Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$14.6 million.

  • Orchestra BioMed Holdings' Cash from Operations fell 620.44% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.2 million, marking a year-over-year decrease of 2549.69%. This contributed to the annual value of -$50.6 million for FY2024, which is 960.61% down from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Cash from Operations stood at -$14.6 million, which was down 620.44% from -$15.5 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Cash from Operations registered a high of -$5.3 million during Q1 2022, and its lowest value of -$16.6 million during Q1 2025.
  • Over the past 4 years, Orchestra BioMed Holdings' median Cash from Operations value was -$11.0 million (recorded in 2023), while the average stood at -$11.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 17011.65% in 2023, then surged by 881.02% in 2024.
  • Orchestra BioMed Holdings' Cash from Operations (Quarter) stood at -$8.7 million in 2022, then dropped by 25.5% to -$11.0 million in 2023, then decreased by 23.36% to -$13.5 million in 2024, then dropped by 7.48% to -$14.6 million in 2025.
  • Its last three reported values are -$14.6 million in Q3 2025, -$15.5 million for Q2 2025, and -$16.6 million during Q1 2025.